In order to identify clinically relevant downstream effectors of androgen signalling, the androgen-regulated kinome was defined in prostate cancer (PCa). Within this study, Choline kinase alpha (CHKA) was identified as an androgen receptor chaperone that is both a biomarker of progression and a potential therapeutic target for PCa.
We profiled the AR-regulated kinome in PCa with a view to demonstrating functionally and clinically important signalling events downstream of the AR.
We showed that choline kinase alpha (CHKA) is a chaperone for the AR, promoting its stability and function 6 . This is the first report demonstrating that kinases can act as chaperones. During our studies we also identified 49 androgen-regulated kinases, of which 25 were up-and 24 down-regulated. We confirmed the in vivo androgen regulation of a subset of these genes in tumour tissue from chemically castrated PCa patients (18/25 androgen up-regulated kinase genes).
CHKA was overexpressed in localised (primary) and metastatic PCa, and decreased in tissues from castrated men. Protein levels of CHKA were correlated with Gleason Grade and Stage and CHKA was an independent predictor of biochemical recurrence. CHKA can exist as two isoforms CHKA2 and CHKA1.
Interestingly, the interaction of CHKA2 with the AR decreased within 5-15 min of androgen treatment, consistent with the timing of AR release from cytoplasmic chaperones and its translocation to the nucleus. AR protein levels were reduced by CHKA knockdown indicating a reciprocal role of CHKA in regulating AR protein levels. A direct physical interaction was mapped between CHKA2 and the LBD of AR (AR LBD ), the AR domain that interacts with HSPs. In a protease protection assay, both DHT and CHKA2 were required to stabilise AR. In line with this, CHKA knockdown did not decrease the levels of an AR variant (ARv567es) lacking the LBD. Taken together, our data show for the first time that kinases can function as protein chaperones -a feature never previously attributed to any kinase.
CHKA inhibition decreased the activity of full length AR, but failed to inhibit AR variants lacking the LBD, indicating that CHKA regulates AR transcriptional activity by binding to AR LBD . Transcriptome sequencing from CHKA knockdown in C4-2 cells found a highly significant bi-directional overlap between siCHKA and androgen-regulated genes, consistent with a global role for CHKA in AR In summary, CHKA can act as a chaperone that regulates AR signalling, elucidating a feed-forward AR-CHKA signalling loop that reinforces AR activity, allowing CHKA to maintain its own expression in PCa. The chaperone function of CHKA confers a growth advantage on PCa by stabilizing the AR in addition to its well-known function in fuelling membrane production through the Kennedy pathway 7 (Figure 1 ), suggesting a de facto role for CHKA as a rate-limiting factor in cancer cell growth.
This discovery should accelerate the screening of potential CHKA inhibitors that will not only inhibit the catalytic function but also decrease the CHKA protein level. We believe our work will direct efforts in the treatment of PCa in particular, but also for other cancers, by stimulating a systematic re-evaluation of CHKA as a therapeutic target in cancers where it is overexpressed and exhibits analogous effects on other oncogenic proteins.
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